ALPN - Alpine Immune Horizon Therapeutics team up to develop therapies for autoimmune and inflammatory diseases

Alpine Immune Sciences (NASDAQ:ALPN) gains 7.7% premarket after announcing an exclusive license and collaboration agreement with Horizon Therapeutics (NASDAQ:HZNP) for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique discovery platform. Under the terms of the agreement, Horizon will make an upfront payment of $25M as well as an equity investment in Alpine of $15M. In addition, Alpine is eligible to receive up to $381M per program, or ~$1.52B in total milestone payments as well as tiered royalties on global net sales. Alpine will advance candidate molecules to pre-defined preclinical milestones. Horizon will then assume responsibility for development and commercialization activities and costs. These candidates include multi-specific fusion protein-based therapeutic candidates for autoimmune and inflammatory diseases.

For further details see:

Alpine Immune, Horizon Therapeutics team up to develop therapies for autoimmune and inflammatory diseases